Dual incretin agonist: difference between revisions
Diff·revision 15 → 16·12:33, 15 Feb 2025
Difference between revision 15 and revision 16 of Dual incretin agonist. 2 lines changed; the page grew by 147 bytes.
| Revision 15 — 12:46, 29 Jan 2025 OrforglipronOona (talk) state plainly that the research-use-only form is not approved for human use 4,587 bytes ±0 | Revision 16 — 12:33, 15 Feb 2025 BacWaterBarnaby (talk) add the year of first marketing authorisation, with the regulator named 4,734 bytes +147 | ||
|---|---|---|---|
| 30 | # ''Restored beta-cell responsiveness''. Beta-cell responsiveness to GIP is impaired in type 2 diabetes but is partly restored when glycaemia improves, so a dual agonist may create the conditions for its own GIP component to work. | 30 | # ''Restored beta-cell responsiveness''. Beta-cell responsiveness to GIP is impaired in type 2 diabetes but is partly restored when glycaemia improves, so a dual agonist may create the conditions for its own GIP component to work. |
| 31 | 31 | ||
| + | 32 | None of the three has been isolated experimentally in humans. The trials were designed to establish efficacy, not to partition it.{{r|frias2021}} | |
| + | 33 | ||
| 32 | == References == | 34 | == References == |
| 33 | {{reflist}} | 35 | {{reflist}} |